Clinical Trial Update: TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating tyrosine kinase inhibitor therapy guided by molecular monitoring in allogeneic stem cell transplant recipients with Phi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Snippet

Sponsor: Nanfang Hospital, Southern Medical University | Conditions: Philadelphia Chromosome Positive Acute Lymphocytic Leukemia, Stem Cell Transplantation | Phase 2 | Status: UNKNOWN